Publications by authors named "Emilio Alba"

Claim this Profile
R
Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy.
Ana Godoy-Ortíz, Gonzalo Lendínez-Sánchez, Manuel Zalabardo, Javier Pascual, Ana López-Pascual, Emilio Alba

Front Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.
Miguel Martín, Angel L Guerrero-Zotano, María E Pérez-López, Manuel Ruiz-Borrego, Noelia Martinez Jañez, Emilio Alba

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ICD-10 Neoplasm Location using Text Classification Models in Spanish Electronic Health Records.
Francisco J Moreno-Barea, Alejandro Pascual-Mellado, Hector Mesa, Beatriz Villaescusa-Gonzalez, Emilio Alba

IEEE J Biomed Health Inform· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luminal and Basal Subtypes Across Carcinomas: Molecular Programs Beyond Tissue of Origin.
Celia Gaona-Romero, María Emilia Domínguez-Recio, Iñaki Comino-Méndez, María Victoria Ortega-Jiménez, Rocío Lavado-Valenzuela, Emilio Alba

Cancers (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Interplay Between Gut Microbiota and the Melatonergic Pathway in Hormone Receptor-Positive Breast Cancer.
Aurora Laborda-Illanes, Soukaina Boutriq, Lucía Aranega-Martín, Daniel Castellano-Castillo, Lidia Sánchez-Alcoholado, Emilio Alba

Int J Mol Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study.
Santiago Escrivá-de-Romani, Juan M Cejalvo, Emilio Alba, Jennifer Friedmann, Álvaro Rodríguez-Lescure

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.
Yara Abdou, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Emilio Alba

J Natl Cancer Inst· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer.
Iñaki Comino-Méndez, Jesús Velasco-Suelto, Javier Pascual, Esperanza López-López, Maria Elena Quirós-Ortega, Emilio Alba

Breast Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a 12-week exercise program on phase angle in women with breast cancer.
Adrian Escriche-Escuder, José Manuel García-Almeida, Isabel María Vegas-Aguilar, Bella Pajares, Emilio Alba

Support Care Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence.
José Ángel García-Saenz, Álvaro Rodríguez-Lescure, Josefina Cruz, Joan Albanell, Emilio Alba

Target Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence.
José Ángel García-Saenz, Álvaro Rodríguez-Lescure, Josefina Cruz, Joan Albanell, Emilio Alba

Target Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Named entity recognition for de-identifying Spanish electronic health records.
Francisco J Moreno-Barea, Guillermo López-García, Héctor Mesa, Nuria Ribelles, Emilio Alba

Comput Biol Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.
Miguel Quintela-Fandino, Begoña Bermejo, Esther Zamora, Fernando Moreno, José Ángel García-Saenz, Emilio Alba

Clin Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.
Sonia Pernas, Esther Sanfeliu, Guillermo Villacampa, Javier Salvador, Antonia Perelló, Emilio Alba

NPJ Breast Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis.
Aurora Laborda-Illanes, Lucía Aranega-Martín, Lidia Sánchez-Alcoholado, Soukaina Boutriq, Isaac Plaza-Andrades, Emilio Alba

Int J Mol Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients.
Alfonso Alba-Bernal, Ana Godoy-Ortiz, María Emilia Domínguez-Recio, Esperanza López-López, María Elena Quirós-Ortega, Emilio Alba

NPJ Breast Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study.
Nuria Ribelles, Javier Pascual, Laura Galvez-Carvajal, Sofía Ruiz-Medina, Javier Garcia-Corbacho, Emilio Alba

JCO Glob Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patients.
Victoria Sánchez-Martín, Esperanza López-López, Diego Reguero-Paredes, Ana Godoy-Ortiz, Maria Emilia Domínguez-Recio, Alfonso Alba-Bernal, Emilio Alba

Clin Chim Acta· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
Sara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, Pau Berenguer-Molins, Marcel Costa-Garcia, Emilio Alba, Joan Albanell

J Exp Clin Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Juan Carlos Vazquez, Silvia Antolin, Manuel Ruiz-Borrego, Sonia Servitja, Emilio Alba

Clin Transl Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Explainable clinical coding with in-domain adapted transformers.
Guillermo López-García, José M Jerez, Nuria Ribelles, Emilio Alba, Francisco J Veredas

J Biomed Inform· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review.
Juan C Vázquez, Antonio Piñero, Francisco J de Castro, Ana Lluch, Miguel Martín, Emilio Alba

Clin Transl Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.
Aurora Laborda-Illanes, Lidia Sánchez-Alcoholado, Daniel Castellano-Castillo, Soukaina Boutriq, Isaac Plaza-Andrades, Emilio Alba

Biomed Pharmacother· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis.
Begoña Jiménez-Rodríguez, Alfonso Alba-Bernal, Esperanza López-López, María Elena Quirós-Ortega, Guillermo Carbajosa, Emilio Alba

Int J Mol Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.
Javier Oliver, Juan Luis Onieva, Maria Garrido-Barros, Miguel-Ángel Berciano-Guerrero, Alfonso Sánchez-Muñoz, Emilio Alba

Biomedicines· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis